Literature DB >> 25754950

Haematological cancer: BCL-ABL1 resistance mutation--breakthrough with axitinib.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25754950     DOI： 10.1038/nrclinonc.2015.42

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Authors:  Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A Repasky; Jeffrey Chen; Peter Wells; Ciarán N Cronin; Michele McTigue; Olli Kallioniemi; Kimmo Porkka; Brion W Murray; Krister Wennerberg
Journal:  Nature       Date:  2015-02-09       Impact factor: 49.962
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.